TScan Therapeutics share price logo

TScan Therapeutics

NASDAQ: TCRX

$0.22

+0.01

(+6.57%)

as on

TScan Therapeutics Stock Performance

as on October 21, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $0.21
    $0.23
    downward going graph

    6.25%

    Downside

    2.68%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $0.20
    $2.55
    downward going graph

    10.09%

    Downside

    1038.39%

    Upside

    downward going graph

TScan Therapeutics share price movements today

Previous Close
$0.21
Open
$0.21
Volume
725.1K
Market Cap
$15.1M
Day's Low - High
$0.21 - $0.23
52 Week Low - High
$0.20 - $2.55

TScan Therapeutics Historical Returns

1 Month Return
-32.61 %
3 Month Return
-77.27 %
1 Year Return
-91.66 %
3 Year Return
-93.33 %
5 Year Return
-97.04 %

TScan Therapeutics Stock Fundamentals & Key Indicators

Check TScan Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$15.1M

EPS (TTM)

-0.91

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.25

Industry PE ratio

-3.10

PEG Ratio

-0.01

EBITDA

-112.0M

Revenue (TTM)

7.1M

Profit Margin

90.25%

Return On Equity TTM

-108.72%

TScan Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of TScan Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Neutral$15.1M-97.04%-0.2590.25%0.00%
Neutral$87.0B-31.87%-27.32-12.57%0.00%
StrongBuy$126.7B170.61%28.8586.04%0.00%
Buy$81.4B38.98%18.8884.86%0.47%

Stock Returns calculator for TScan Therapeutics Stock including INR - Dollar returns

The TScan Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 10Y

TScan Therapeutics investment value today

Current value as on today

₹9,603

Returns

-₹90,397

(-90.4%)

Returns from TScan Therapeutics Stock

-₹91,111 (-91.11%)

Dollar Impact

₹714 (+0.71%)

Analyst Recommendation on TScan Therapeutics Stock

Based on 6 analysts

HOLD

16.67%

Buy

83.33%

Hold

0.00%

Sell

Based on 6 analysts, 83.33333333333334% of analysts recommend a 'HOLD' rating for TScan Therapeutics. Average target price of $1

TScan Therapeutics Share Price Target

Get share price movements and forecasts by analysts on TScan Therapeutics.

What analysts predicted

77.6%UPSIDE

Target Price

$1

Current Price

$0.224

Analyzed by

6 Analysts

High

$1

Target

$1.00

Low

$1

TScan Therapeutics target price $1, a slight upside of 77.6% compared to current price of $0.224. According to 6 analysts rating.

Indian Investors' Interest in TScan Therapeutics Stock

Search interest for TScan Therapeutics Stock has decreased by -41% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-41% versus previous 30 day period

TScan Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
0
0
1
0
2
3
2
2
0
1
Gross Profit
0
0
1
0
2
3
2
2
0
1
Operating Income
-31
-34
-32
-36
-36
-38
-37
-23
-29
-30
EBITDA
-27
-29
-27
-34
-32
-35
-34
-21
-27
-28
Interest Expense
0
0
0
0
0
0
0
0
0
0
Depreciation
1
1
1
0
0
0
0
0
0
0
Income Before Tax
-30
-31
-29
-35
-34
-36
-35
-22
-28
-30
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-30
-31
-29
-35
-34
-36
-35
-22
-28
-30
Net Profit Margin
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
29.43%
100.00%

TScan Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
1
10
13
21
2
10
Gross Profit
-9
-19
10
13
21
2
7
Operating Income
-14
-26
-48
-66
-93
-134
-135
EBITDA
-13
-25
-45
-59
-80
-119
-124
Interest Expense
-
-
-
1
3
3
2
Depreciation
0
1
3
5
5
4
2
Income Before Tax
-13
-26
-48
-66
-89
-127
-129
Income Tax Expense
-
-
-
-
-
-
-
Net Income
-13
-26
-48
-66
-89
-127
-129
Net Profit Margin
0.00%
-1796.50%
100.00%
100.00%
100.00%
100.00%
72.24%

TScan Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-30
-31
-29
-35
-34
-36
-35
-22
-28
-30
Operating Cash Flow
-29
-26
-27
-27
-37
-33
-32
-32
-24
-27
Investing Cash Flow
36
-33
-82
27
13
48
32
14
0
0
Financing Cash Flow
0
161
1
45
0
0
-
0
-
0
Change in Cash
7
101
-109
45
-24
15
0
-17
-24
-27

TScan Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-13
-26
-48
-66
-89
-127
-129
Operating Cash Flow
-12
-3
-48
-66
-61
-110
-135
Investing Cash Flow
-1
-4
-9
-4
-60
-52
109
Financing Cash Flow
34
0
189
29
135
208
0
Change in Cash
21
-6
131
-41
13
45
-26

Global Institutional Holdings in TScan Therapeutics

Check out the Institutions with significant holdings in TScan Therapeutics.

Funds
Holdings
Felix Baker
4.39%
Vanguard
3.95%
VANGUARD INDEX FUNDS
3.27%
BlackRock Funds
0.88%
Fidelity Concord Street Trust
0.73%

TScan Therapeutics News & Key Events

  • img

    Today's Timeline - 02 September

    Wed, 05:29 PM

    -

    TScan Therapeutics announces strategic reorganization, focusing on solid tumors and reducing workforce by 75% amid financial pressures.

Insights on TScan Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 982.0K → 1.05M (in $), with an average increase of 6.6% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 780.6% return, outperforming this stock by 871.0%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 201.1% return, outperforming this stock by 294.0%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, TCRX stock has moved down by -32.2%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, -22.97M → -30.35M (in $), with an average decrease of 15.3% per quarter

About TScan Therapeutics

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
OrganisationTScan Therapeutics
Headquarters830 Winter Street, Waltham, MA, 02451, US
IndustryBiotechnology
CEOGavin MacBeath

Key Management of TScan Therapeutics

Name

Title

Mr. Tomasz Kula Ph.D.

Co-Founder & Member of Advisory Board

Dr. Zoran Zdraveski J.D., Ph.D.

Chief Legal & Strategy Officer and Company Secretary

Ms. Ann Hargraves

Chief Human Resources Officer

Dr. Shrikanta Chattopadhyay M.D.

Senior VP & Head of Translational Medicine

Mr. Jim Murray

Chief Development Operations Officer

Mr. Cagan Gurer Ph.D.

Senior Vice President of Discovery

Dr. Gavin MacBeath Ph.D.

CEO, Principal Financial Officer, Principal Accounting Officer & Director

Dr. Stephen J. Elledge Ph.D.

Co-Founder & Chairman of Scientific Advisory Board

FAQs

What is TScan Therapeutics share price today?

TScan Therapeutics share price today is $0.22 as on at the close of the market. TScan Therapeutics share today touched a day high of $0.23 and a low of $0.21.

What is the 52 week high and 52 week low for TScan Therapeutics share?

TScan Therapeutics share touched a 52 week high of $2.55 on and a 52 week low of $0.20 on . TScan Therapeutics stock price today i.e. is closed at $0.22,which is 91.22% down from its 52 week high and 11.22% up from its 52 week low.

What is TScan Therapeutics's market capitalisation today?

TScan Therapeutics market capitalisation is $0.00T as on .

How to invest in TScan Therapeutics Stock (TCRX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for TScan Therapeutics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy TScan Therapeutics Stock (TCRX) from India?

Indian investors can start investing in TScan Therapeutics (TCRX) shares with as little as ₹94.93000030517578 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.30 in TScan Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on TScan Therapeutics share’s latest price of $0.22 as on October 21, 2026 at 8:45 am IST, you will get 44.6429 shares of TScan Therapeutics. Learn more about fractional shares .

What are the returns that TScan Therapeutics has given to Indian investors in the last 5 years?

TScan Therapeutics stock has given -97.04% share price returns and 26.89% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?